Drew Deniger - 29 Mar 2022 Form 3 Insider Report for Alaunos Therapeutics, Inc. (TCRT)

Role: VP, Research & Development
Signature: /s/ Drew Deniger
Issuer symbol: TCRT
Transactions as of: 29 Mar 2022
Net transactions value: $0
Form type: 3
Filing time: 08 Apr 2022, 16:30:24 UTC
Next filing: 19 Sep 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	TCRT	Common Stock						15,000	29 Mar 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TCRT	Employee Stock Option (right to buy)							29 Mar 2022	Common Stock	50,000	$4.13	Direct	F1
holding	TCRT	Employee Stock Option (right to buy)							29 Mar 2022	Common Stock	30,000	$4.72	Direct	F2
holding	TCRT	Employee Stock Option (right to buy)							29 Mar 2022	Common Stock	75,000	$2.82	Direct	F3
holding	TCRT	Employee Stock Option (right to buy)							29 Mar 2022	Common Stock	35,000	$4.31	Direct	F4
holding	TCRT	Employee Stock Option (right to buy)							29 Mar 2022	Common Stock	250,000	$1.50	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option was granted on September 24, 2019. One-fourth of the shares underlying the option vested on September 24, 2020, and the remainder vests in twelve successive equal quarterly installments measured from September 24, 2020, subject to the Reporting Person's continued service through each such date.
F2	The option was granted on December 31, 2019. One-twelfth of the shares underlying the option vest in equal quarterly installments commencing three months after the grant date, subject to the Reporting Person's continued service through each such date.
F3	The option was granted on January 4, 2021. One-twelfth of the shares underlying the option vest in equal quarterly installments commencing three months after the grant date, subject to the Reporting Person's continued service through each such date.
F4	The option was granted on March 4, 2021. One-sixteenth of the shares underlying the option vest in equal quarterly installments commencing three months after December 31, 2020, subject to the Reporting Person's continued service through each such date.
F5	The option was granted on October 29, 2021. One-sixteenth of the shares underlying the option vest in equal quarterly installments commencing three months after the grant date, subject to the Reporting Person's continued service through each such date.